{"entity":{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","aka":[],"tldr":"In ADCC, an antibody flags a cell, and NK cells recognise the flag and kill it.","summary":"ADCC, antibody-dependent cellular cytotoxicity, is the process in which an antibody flags a cell and NK cells recognise the flag and kill it. It is mediated by the interaction between the antibody Fc region and FcγRIIIa (CD16) on the NK cell, and it can be enhanced by afucosylating the antibody, as in obinutuzumab, margetuximab and belantamab. ADCC contributes to the activity of trastuzumab, rituximab and cetuximab, and the mechanism belongs to the Monoclonal antibodies technology entry. Drug records that cite it include Margetuximab, Zolbetuximab, Obinutuzumab, Rituximab, Tafasitamab, Daratumumab, Mogamulizumab, Elotuzumab and Dinutuximab (ch14.18) / dinutuximab beta, and it is referenced by the Gastric & gastro-oesophageal junction cancer and Neuroblastoma (paediatric) entries.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Antibody-dependent_cellular_cytotoxicity","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Antibody-dependent_cellular_cytotoxicity"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Immunology"},"route":"/terms/adcc/","neighbours":{"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"drug":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/"},{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/"},{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/"},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/"},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/"}],"target":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"},{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/"},{"id":"slamf7","kind":"target","name":"SLAMF7 (CS1)","route":"/targets/slamf7/"}],"paper":[{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/"}],"term":[{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/"},{"id":"nk-cell","kind":"term","name":"NK cell","route":"/terms/nk-cell/"}],"institution":[{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/"}],"pathway":[{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/"},{"id":"extrinsic-apoptosis-death-receptors","kind":"pathway","name":"Extrinsic apoptosis (death receptors)","route":"/pathways/extrinsic-apoptosis-death-receptors/"},{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/"},{"id":"rtk-activation","kind":"pathway","name":"Receptor tyrosine kinase activation","route":"/pathways/rtk-activation/"}]}}